We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
- Authors
Ishida, Kazuo; Kaku, Mitsuo; Irifune, Kenji; Mizukane, Ryusuke; Takemura, Hiromu; Yoshida, Ryouji; Tanaka, Hironori; Usui, Toshiaki; Tomono, Kazunori; Suyama, Naofumi; Koga, Hironobu; Kohno, Shigeru; Hara, Kohei; Ishida, K; Kaku, M; Irifune, K; Mizukane, R; Takemura, H; Yoshida, R; Tanaka, H
- Abstract
We investigated the in-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae, and compared it with ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin and minocycline. AM-1155 was the most potent agent in vitro of the quinolones tested. Its pre-treatment minimal inhibitory concentrations for 90% of the 41 strains (MIC90) was 0.06 mg/L. In contrast, pre-treatment MIC90 values for ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin, and minocycline were 1, 1, 2, 0.5, 0.0156, and 0.5 mg/L, respectively. Post-treatments MIC90s, which may reflect mycoplasmacidal potency, of AM-1155, ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin and minocycline were 0.125, 1, 2, 4, 0.5, 0.125 and 4 mg/L, respectively. In-vitro activities of antimicrobial agents were assessed in an experimental pulmonary infection model in Syrian golden hamsters. AM-1155 was the most effective agent among five antimicrobial agents (AM-1155, ofloxacin, tosufloxacin, erythromycin, minocycline) tested in terms of reduction in viable M. pneumoniae cells and in reducing macroscopic lung lesions. These results suggest that AM-1155 will be a useful antimicrobial agent for the treatment of M. pneumoniae infections.
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 1994, Vol 34, Issue 6, p875
- ISSN
0305-7453
- Publication type
journal article